Answers are grounded in this paper and cite their sources.
Drug prescription review is a key link in ensuring patient medication safety and improving the quality of medicine. The traditional manual review model is limited by human resources, the speed of information updates and individual experience differences, making it difficult to cope with the increasingly complex environment of medication review. This article is a narrative review of the development history, core technical architecture, main application models, implementation benefits, and the challenges and future trends of information-based drug prescription review. Rule engines, clinical decision support, machine learning and generative artificial intelligence have extended review from static rule checking towards risk prediction and text understanding, but these technologies differ substantially in validation, interpretability and maturity. Information-based review achieves real-time, standardised interception and alerting of prescription risks at scale and reduces the rate at which recognised prescribing errors reach the patient; the evidence for reductions in preventable adverse drug events and in patient outcomes such as admissions and mortality is, however, weaker, heterogeneous and dominated by single-centre or before-and-after designs. System limitations, clinical adaptability, data quality, alert fatigue, interoperability, equity and law still require attention, and future value will depend less on algorithmic sophistication than on validation in real settings, interoperable data and human oversight.
No takes yet. Share an insight, caveat, or question.
Le et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: